Literature DB >> 28461250

Deletion of exons 9 and 10 of the Presenilin 1 gene in a patient with Early-onset Alzheimer Disease generates longer amyloid seeds.

Kilan Le Guennec1, Sarah Veugelen2, Olivier Quenez1, Maria Szaruga2, Stéphane Rousseau1, Gaël Nicolas1, David Wallon3, Frédérique Fluchere4, Thierry Frébourg5, Bart De Strooper6, Dominique Campion7, Lucía Chávez-Gutiérrez2, Anne Rovelet-Lecrux8.   

Abstract

Presenilin 1 (PSEN1) mutations are the main cause of autosomal dominant Early-onset Alzheimer Disease (EOAD). Among them, deletions of exon 9 have been reported to be associated with a phenotype of spastic paraparesis. Using exome data from a large sample of 522 EOAD cases and 584 controls to search for genomic copy-number variations (CNVs), we report here a novel partial, in-frame deletion of PSEN1, removing both exons 9 and 10. The patient presented with memory impairment associated with spastic paraparesis, both starting from the age of 56years. He presented a positive family history of EOAD. We performed functional analysis to elucidate the impact of this novel deletion on PSEN1 activity as part of the γ-secretase complex. The deletion does not affect the assembly of a mature protease complex but has an extreme impact on its global endopeptidase activity. The mutant carboxypeptidase-like activity is also strongly impaired and the deleterious mutant effect leads to an incomplete digestion of long Aβ peptides and enhances the production of Aβ43, which has been shown to be potently amyloidogenic and neurotoxic in vivo.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer Disease; Amyloid; Aβ43; Early-onset; Hydrophilic loop; PSEN1

Mesh:

Substances:

Year:  2017        PMID: 28461250     DOI: 10.1016/j.nbd.2017.04.020

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  10 in total

Review 1.  The contribution of CNVs to the most common aging-related neurodegenerative diseases.

Authors:  Giulia Gentile; Valentina La Cognata; Sebastiano Cavallaro
Journal:  Aging Clin Exp Res       Date:  2020-02-06       Impact factor: 3.636

2.  Novel presenilin 1 and 2 double knock-out cell line for in vitro validation of PSEN1 and PSEN2 mutations.

Authors:  Anna A Pimenova; Alison M Goate
Journal:  Neurobiol Dis       Date:  2020-02-04       Impact factor: 5.996

3.  Progressive cognitive impairment and familial spastic paraparesis due to PRESENILIN 1 mutation: anatomoclinical characterization.

Authors:  Miren Altuna; Rosa Larumbe; María Victoria Zelaya; Sira Moreno; Virginia García-Solaesa; Maite Mendioroz; María Antonia Ramos; María Elena Erro
Journal:  J Neurol       Date:  2022-04-19       Impact factor: 6.682

Review 4.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

Review 5.  Warning SINEs: Alu elements, evolution of the human brain, and the spectrum of neurological disease.

Authors:  Peter A Larsen; Kelsie E Hunnicutt; Roxanne J Larsen; Anne D Yoder; Ann M Saunders
Journal:  Chromosome Res       Date:  2018-02-19       Impact factor: 5.239

Review 6.  RNA Editing and Retrotransposons in Neurology.

Authors:  Heinz Krestel; Jochen C Meier
Journal:  Front Mol Neurosci       Date:  2018-05-23       Impact factor: 5.639

Review 7.  Transcriptomics in Alzheimer's Disease: Aspects and Challenges.

Authors:  Eva Bagyinszky; Vo Van Giau; SeongSoo A An
Journal:  Int J Mol Sci       Date:  2020-05-15       Impact factor: 5.923

8.  Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer's Disease.

Authors:  Emilie Faivre; Joana E Coelho; Katja Zornbach; Enas Malik; Younis Baqi; Marion Schneider; Lucrezia Cellai; Kevin Carvalho; Shéhérazade Sebda; Martin Figeac; Sabiha Eddarkaoui; Raphaëlle Caillierez; Yijuang Chern; Michael Heneka; Nicolas Sergeant; Christa E Müller; Annett Halle; Luc Buée; Luisa V Lopes; David Blum
Journal:  Front Mol Neurosci       Date:  2018-07-12       Impact factor: 5.639

9.  Alternative splicing in a presenilin 2 variant associated with Alzheimer disease.

Authors:  Jacquelyn E Braggin; Stephanie A Bucks; Meredith M Course; Carole L Smith; Bryce Sopher; Leah Osnis; Kiel D Shuey; Kimiko Domoto-Reilly; Christina Caso; Chizuru Kinoshita; Kathryn P Scherpelz; Chloe Cross; Thomas Grabowski; Seyyed H M Nik; Morgan Newman; Gwenn A Garden; James B Leverenz; Debby Tsuang; Caitlin Latimer; Luis F Gonzalez-Cuyar; Christopher Dirk Keene; Richard S Morrison; Kristoffer Rhoads; Ellen M Wijsman; Michael O Dorschner; Michael Lardelli; Jessica E Young; Paul N Valdmanis; Thomas D Bird; Suman Jayadev
Journal:  Ann Clin Transl Neurol       Date:  2019-03-10       Impact factor: 4.511

Review 10.  Recent Advances in the Modeling of Alzheimer's Disease.

Authors:  Hiroki Sasaguri; Shoko Hashimoto; Naoto Watamura; Kaori Sato; Risa Takamura; Kenichi Nagata; Satoshi Tsubuki; Toshio Ohshima; Atsushi Yoshiki; Kenya Sato; Wakako Kumita; Erika Sasaki; Shinobu Kitazume; Per Nilsson; Bengt Winblad; Takashi Saito; Nobuhisa Iwata; Takaomi C Saido
Journal:  Front Neurosci       Date:  2022-03-31       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.